
NICE is still not recommending GlaxoSmithKline’s lupus drug Benlysta, as it believes the treatment is too costly. In its final …
The chief executive of NICE acknowledges changes are needed in how drugs are assessed in the UK – including more …
NICE received no warning that its health technology assessment role is to be downgraded, the watchdog’s head has admitted. In …

Andrew Dillon, chief executive of the National Institute for Health and Clinical Excellence (NICE), has been knighted in the 2010 …

